First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease

    loading  Checking for direct PDF access through Ovid

Excerpt

Levodopa is the most effective symptomatic treatment throughout the course of Parkinson's disease (PD), but as the disease progresses, patients may develop motor fluctuations, manifested as end‐of‐dose deterioration and/or dyskinesia. This may be countered by individualized, fractionized, fine‐tuned treatments.1
The levodopa/carbidopa microtablets,2 5/1.25 mg (LC‐5, Flexilev®, Sensidose® AB, Sollentuna, Sweden), dispensed with the automatic dose dispenser4 MyFID™, were used in Sweden on licensed prescription from 2013. The treatment was approved in 2014 by the MPA in Sweden and recently approved (2016) by the EMA in 13 EU countries following the mutual recognition procedure. The dose dispenser is equipped with an alarm to facilitate treatment adherence, and a diary function, enabling patient self‐reporting of symptoms and disease overview.
The aim of this evaluation was to assess the initial experience of the treatment with LC‐5 and the dose dispenser with respect to efficacy and usability.
    loading  Loading Related Articles